BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 26282635)

  • 21. Oxaliplatin treatment and peripheral nerve damage in cancer patients: A Polish cohort study.
    Banach M; Zygulska AL; Krzemieniecki K
    J Cancer Res Ther; 2018; 14(5):1010-1013. PubMed ID: 30197340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
    Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
    Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
    Vincenzi B; Frezza AM; Schiavon G; Spoto C; Silvestris N; Addeo R; Catalano V; Graziano F; Santini D; Tonini G
    Support Care Cancer; 2013 May; 21(5):1313-9. PubMed ID: 23196819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
    Soveri LM; Lamminmäki A; Hänninen UA; Karhunen M; Bono P; Osterlund P
    Acta Oncol; 2019 Apr; 58(4):398-406. PubMed ID: 30638100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
    Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
    Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer.
    Teng C; Reuter SE; Blinman PL; Dhillon HM; Galettis P; Proschogo N; McLachlan AJ; Vardy JL
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):547-558. PubMed ID: 32949265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
    Takeshita E; Ishibashi K; Koda K; Oda N; Yoshimatsu K; Sato Y; Oya M; Yamaguchi S; Nakajima H; Momma T; Maekawa H; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Ishida H
    Surg Today; 2021 Aug; 51(8):1309-1319. PubMed ID: 33586034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
    Cao Y; Chang Q; Zhang W; Ornatsky O; Hedley D; Chen EX
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1195-1200. PubMed ID: 31520102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
    Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
    Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
    Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
    Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting acute and persistent neuropathy associated with oxaliplatin.
    Alejandro LM; Behrendt CE; Chen K; Openshaw H; Shibata S
    Am J Clin Oncol; 2013 Aug; 36(4):331-7. PubMed ID: 22547012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
    Tatsushima Y; Egashira N; Narishige Y; Fukui S; Kawashiri T; Yamauchi Y; Oishi R
    Biomed Pharmacother; 2013 Feb; 67(1):39-42. PubMed ID: 23206755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
    Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
    Kanai M; Kawaguchi T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Ishigure K; Hasegawa J; Munemoto Y; Matsui T; Takagane A; Ishikawa H; Matsumoto S; Sakamoto J; Saji S; Yoshino T; Ohtsu A; Watanabe T; Matsuda F
    Ann Oncol; 2016 Jun; 27(6):1143-1148. PubMed ID: 27069012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute pain associated with oxaliplatin infusion: case report and literature review.
    Clay TD; Ashley DA
    J Oncol Pharm Pract; 2012 Dec; 18(4):421-4. PubMed ID: 22080592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
    Hsu HT; Wu LM; Lin PC; Juan CH; Huang YY; Chou PL; Chen JL
    Medicine (Baltimore); 2020 Feb; 99(6):e19029. PubMed ID: 32028414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.